Shinya Furukawa

Prof. Shinya Furukawa

Ehime University, Matsuyama, Ehime, Japan
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
Shinya FurukawaShinya Furukawa
Shinya Furukawa
ISIsao Saito
Isao Saito
SYShin Yamamoto
Shin Yamamoto
TMTeruki Miyake
Teruki Miyake
TUTeruhisa Ueda
Teruhisa Ueda
TTTakeshi Tanigawa
Takeshi Tanigawa
Objective: We estimated the prevalence of nocturnal intermittent hypoxia, a surrogate marker of obstructive sleep apnoea, among type 2 diabetes mellitus (T2DM) patients and examined the association between nocturnal intermittent hypoxia and microvascular diseases.Design and methods: We recruited 513 Japanese patients (292 men and 221 women) with T2DM. Nocturnal intermittent hypoxia was diagnosed using the 3% oxygen desaturation index, with less than five events per hour corresponding to normal and five events or more per hour corresponding to nocturnal intermittent hypoxia.Results: The prevalence of nocturnal intermittent hypoxia was 45.4% among T2DM patients. The nocturnal intermittent hypoxia group was older and had a higher BMI, greater weight change since the age of 20 years, higher smoking rate and increased prevalence of hypertension, hyperlipidaemia, microalbuminuria and macroalbuminuria. Microalbuminuria (model 1: odds ratio (OR), 3.41; 95% CI, 1.85–6.40; model 2: OR, 3.69; 95% CI, 1.85–7.59 and model 3: OR, 3.12; 95% CI, 1.45–6.95) and nephropathy (model 1: OR, 4.51; 95% CI, 1.58–15.1; model 2: OR, 7.31; 95% CI, 2.11–31.6 and model 3: OR, 5.23; 95% CI, 1.45–23.8) were derived as factors from all the three statistical models and constantly associated with nocturnal intermittent hypoxia only in women.Conclusions: Nocturnal intermittent hypoxia was highly prevalent among T2DM patients and may be an independent associated risk factor for microalbuminuria in Japanese women with T2DM.

31 August 2013 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
TKTaira Kuroda
Taira Kuroda
TKTeru Kumagi
Teru Kumagi
TYTomoyuki Yokota
Tomoyuki Yokota
HSHirotaka Seike
Hirotaka Seike
MNMari Nishiyama
Mari Nishiyama
MOMorikazu Onji
Morikazu Onji
Although the outcomes of pancreatic cancer have been improved by gemcitabine, the changes in its characteristics and long-term outcomes within the gemcitabine era remain unclear. This study was conducted to identify clinical characteristics of pancreatic cancer patients within the gemcitabine era. A retrospective chart review was performed at 10 centers for 1,248 consecutive patients who were ever considered to have a diagnosis of pancreatic cancer between 2001 and 2010. Data collected included demographics, diagnosis date, clinical stage, treatment, and outcome; 1,082 patients met the inclusion criteria and were analyzed further. The chi-square test, Student’s t-test, and Mann–Whitney U-test were used for statistical analysis. Outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards regression. Differences in survival analyses were determined using the log-rank test. The distribution of clinical stages was: I, 2.2%; II, 3.4%; III, 13%; IVa, 27%; and IVb, 55%. Chemotherapy alone was administered to 42% of patients and 17% underwent resection. The 1-, 3-, and 5-year survival rates were 39%, 13%, and 6.9%, respectively. The median survival time was 257 days, but differed considerably among treatments and clinical stages. Demographics, distribution of clinical stage, and cause of death did not differ between groups A (2001–2005, n = 406) and B (2006–2010, n = 676). However, group B included more patients who underwent chemotherapy (P < 0.0001) and fewer treated with best supportive care (P = 0.0004), mirroring improvements in this group’s long-term outcomes (P = 0.0063). Finally, factors associated with long-term outcomes derived from multivariate analysis were clinical stage (P < 0.0001), location of the tumor (P = 0.0294) and treatments (surgery, chemotherapy) (P < 0.0001). Long-term outcomes in pancreatic cancer has improved even within the gemcitabine era, suggesting the importance of offering chemotherapy to patients previously only considered for best supportive care. Most patients are still diagnosed at an advanced stage, making clinical strategy development for diagnosing pancreatic cancer at earlier stages essential.

10 March 2005 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SASk. Md. Fazle Akbar
Sk. Md. Fazle Akbar
Shinya FurukawaShinya Furukawa
Shinya Furukawa
SNSeiji Nakanishi
Seiji Nakanishi
MAMasanori Abe
Masanori Abe
NHNorio Horiike
Norio Horiike
MOMorikazu Onji
Morikazu Onji

1 July 2016 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
HSHidenori Senba
Hidenori Senba
Shinya FurukawaShinya Furukawa
Shinya Furukawa
TSTakenori Sakai
Takenori Sakai
TNTetsuji Niiya
Tetsuji Niiya
TMTeruki Miyake
Teruki Miyake
Yoshihiro MiyakeYoshihiro Miyake
Yoshihiro Miyake

18 July 2017 in Tobacco Induced Diseases
Verified
Journal Article
Open access
KTKeiko Tanaka
Keiko Tanaka
Yoshihiro MiyakeYoshihiro Miyake
Yoshihiro Miyake
Shinya FurukawaShinya Furukawa
Shinya Furukawa
MAMasashi Arakawa
Masashi Arakawa
Background: Evidence regarding the independent and additive effects of both pre- and postnatal smoking exposure on the risk of wheeze in children is limited. The purpose of this prospective pregnancy birth cohort study was to examine the association between prenatal and postnatal tobacco smoke...

30 April 2022 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
YYYasunori Yamamoto
Yasunori Yamamoto
Shinya FurukawaShinya Furukawa
Shinya Furukawa
JWJunichi Watanabe
Junichi Watanabe
AKAki Kato
Aki Kato
KKKatsunori Kusumoto
Katsunori Kusumoto
YHYoichi Hiasa
Yoichi Hiasa
Yasunori Yamamoto, Shinya Furukawa, Junichi Watanabe, Aki Kato, Katsunori Kusumoto, Eiji Takeshita, Yoshio Ikeda, Naofumi Yamamoto, Katsuhiko Kohara, Yuka Saeki, and Yoichi Hiasa. J Neurogastroenterol Motil 2022;28:276-82. https://doi.org/10.5056/jnm21076